Meghana Keshavan covers biotech and contributes to The Readout newsletter. Pfizer and Valneva’s Lyme disease vaccine cut cases by about 73% in a Phase 3 trial, but missed its primary statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results